Cell therapies are moving from clinical trials into commercial-scale production, as both U.S. and EU regulators accelerate pathways for innovative treatments. By 2025, over 65% of advanced therapy medicinal products (ATMPs) in development are expected to enter early commercialization in specialized facilities, scaling to 85% by 2030. The market is projected to grow from USD 12.4 billion in 2025 to USD 28.1 billion by 2030, driven by oncology, autoimmune disorders, and rare disease indications.

‍

Manufacturing scale-up remains a significant challenge, with batch-to-batch variability, cleanroom capacity, and automated bioreactor systems at the forefront. Early adopters in the U.S. and EU are reporting production yield increases of 20–30%, while cost per dose is expected to decline by 15–20% with modular and automated production platforms. Regulatory frameworks in the EU (EMA ATMP guidelines) and the U.S. (FDA Regenerative Medicine Advanced Therapy (RMAT) designation) are streamlining approval processes, but compliance costs are still high, averaging $4–6 million per facility per year. Strategic partnerships and contract manufacturing organizations (CMOs) are playing a key role in market entry and global distribution.

‍

Cell therapy commercialization is no longer experimental scaling production, navigating global regulations, and leveraging innovative manufacturing platforms are essential for sustainable growth and competitive market entry in the U.S. and EU.

‍

 5 Key Quantitative Takeaways (2025–2030):

‍

• Market growth: USD 12.4B → USD 28.1B
• Advanced therapy commercialization: 65% → 85% by 2030
• Production yield improvements: 20–30%
• Cost per dose reduction: 15–20%
• Regulatory compliance costs: $4–6M per facility per year
  
  

Download the full report to explore manufacturing scale-up strategies, regulatory pathways, and commercialization frameworks for cell therapy in U.S. and EU markets.

• Cell therapy commercialization 2025–2030
• Advanced therapy medicinal products (ATMPs)
• Manufacturing scale-up cell therapy
• Automated bioreactor production
• Oncology cell therapy market
• Rare disease regenerative medicine
• EMA ATMP guidelines Europe
• FDA RMAT designation US
• Contract manufacturing organizations (CMOs)
• Modular cell therapy production
• Regulatory compliance costs cell therapy
• Global market entry cell therapy

• Request a Customized Transcript: Submit your own questions or specify changes. We’ll conduct a new call with the industry expert, covering both the original and your additional questions. You’ll receive an updated report for a small fee over the standard price.
• Request a Direct Call with the Expert: If you prefer a live conversation, we can facilitate a call between you and the expert. After the call, you’ll get the full recording, a verbatim transcript, and continued platform access to query the content and more.

‍